Results 11 to 20 of about 39,201 (181)
Reactions Weekly, 2023 Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed to treat hepatitis C, but it was later tested for Ebola virus sickness and Marburg virus ...
Bakheit, Ahmed H. +3 more
+16 more sources
Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions [PDF]
Journal of Pharmacy & Pharmaceutical Sciences, 2021 Purpose: Remdesivir, a drug originally developed against Ebola virus, is currently recommended for patients hospitalized with coronavirus disease of 2019 (COVID-19).
Subrata Deb, Anthony Allen Reeves
doaj +2 more sources
Tetrahedron Letters, 2022 Remdesivir, the first drug approved by the FDA to treat COVID-19, is in high demand for patients infected with the SARS-CoV-2 virus. Herein, we report a facile approach minimizing the protecting group manipulations to afford remdesivir in good overall yield.
Kumar Palli, Kishore +9 more
openaire +3 more sources
Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters [PDF]
Pharmaceutics, 2021 Remdesivir has been approved for treatment of COVID-19 and shortens the time to recovery in hospitalized patients. Drug transporters removing remdesivir from the circulation may reduce efficacy of treatment by lowering its plasma levels.
Anne T. Nies +5 more
doaj +2 more sources
Effectiveness and Safety of Nirmatrelvir/Ritonavir (Paxlovid) Versus Remdesivir in COVID-19: A Systematic Review and Meta-Analysis of Retrospective Studies. [PDF]
Health Sci RepABSTRACT Background and Aim Nirmatrelvir/ritonavir (Paxlovid) and remdesivir are antiviral agents that have been widely used in the management of patients with Coronavirus disease 2019 (COVID‐19). This systematic review and meta‐analysis were conducted to compare the clinical effectiveness and safety outcomes of Paxlovid and remdesivir among patients ...
Akbarzadeh A +7 more
europepmc +2 more sources
Remdesivir and Lopinavir/Ritonavir as Potential Drugs to Treat Corona Virus Disease 2019 [PDF]
, 2021 Drugs that are efficacious against SARS-CoV-2 have yet to be established. Remdesivir and Lopinavir/ritonavir have garnered considerable attention for their potential to treat coronavirus disease 2019 (COVID-19).
Sanaa Bouchnafati +3 more
core +1 more source
A Potential Practical Process for Remdesivir [PDF]
, 2021 A four-step synthesis of Remdesivir (1) is presented. This work focuses on the yield improvement of step 1, flow chemistry development of step 2 and 3, process optimization of step 4.
Miao, Wu +7 more
core +1 more source
Impact of Remdesivir Incorporation Along the Primer Strand on SARS-CoV-2 RNA-dependent RNA polymerase [PDF]
, 2022 Remdesivir was the first antiviral drug that received emergency use authorization from the United States Food and Drug Administration and is now formally approved to treat COVID-19.
Sehr, Naseem-Khan +4 more
core +2 more sources
1’-cyano substitution of Remdesivir “template-dependent” inhibiting the transcription of SARS-CoV-2 [PDF]
, 2022 Remdesivir is one nucleotide analog prodrug capable to terminate RNA synthesis in SARS-CoV-2 RdRp by two distinct mechanisms. The “delayed chain termination mechanism” has been extensively investigated, while the “template-dependent inhibition mechanism”
Xueying, Luo +3 more
core +2 more sources